Festive launch of Uniferon® in Poland

December 19, 2012

When our new partner Vetoquinol BIOWET recently launched Uniferon in Poland, it was celebrated in style.

The renowned Polish company invited their sales personal to a very inspiring sales meeting/launch event. And they went to great lengths to kick things off in a proper manner.

Among other things the sales team received a copy of "The Swineherd" by Danish author Hans Christian Andersen, Danish delicacies were served at the dinner event, and the whole event included several national Danish trademarks to set the scene.

International Sales Manager Christian von der Recke attended the sales meeting and states: "At Pharmacosmos, we sincerely applaud the creativity shown, and we thank Vetoquinol BIOWET for the great idea and the warm welcome onto the very promising Polish market for injectable quality iron."

On this note, we want to thank you all for an exciting 2012, where Uniferon was launched not only in Poland, but also in France, Russia, Portugal and in the Baltic countries as well as becoming available in all Scandinavian countries.

We are delighted to continuously pursue best practice iron management together with winning pig farmers everywhere, and we feel confident that 2013 will be equally exciting.

We wish you all a Merry Christmas and a happy New Year.

About Uniferon

Uniferon is a modern improved iron hydrogenated dextran based on a natural formula, which is approved for global use:

Uniferon is manufactured without the use of any organic solvents or cyanide, thus, avoiding trace residues of these impurities. Pharmacosmos manufactures iron dextran of high quality and unique purity for customers worldwide. Uniferon is the only injectable iron brand for piglets approved in the EU, the US and Asia.

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.